Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 12/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30585984 | 1.00 | APLNR (0.52) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14921907 | 0.86 | APLNR (0.54) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL352828 | 0.85 | APLNR (0.50) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17048617 | 0.82 | APLNR (0.50) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18062214 | 0.80 | APLNR (0.59) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3160157 | 0.80 | APLNR (0.52) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17048535 | 0.79 | NPC1 (0.48) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30585654 | 0.79 | APLNR (0.46) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21640504 | 0.79 | APLNR (0.46) | APLNRTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1094314 | 0.78 | APLNR (0.54) | APLNRTSHRCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | APLNR 2172/4885TSHR 1378/4885CYP1A2 1065/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | APLNR 1542/4885TSHR 1343/4885CYP1A2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.